Accessibility StatementSkip Navigation DUBLIN, Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Mr. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company's management committee. "I'm delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes' strong financial foundation and advance its s ...

Accessibility StatementSkip Navigation — Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/or Schizophrenia — — Application Period to Run From Sept. 15, 2025 Through Dec. 15, 2025 — DUBLIN, Sept. 11, 2025 /PRNewswire/ --Â Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards program ...

Company Overview - Alkermes plc (NASDAQ: ALKS) is a biopharmaceutical company focused on developing innovative medicines for central nervous system (CNS) disorders, including schizophrenia, depression, and addiction. The company operates in a competitive landscape with peers like Biogen and Eli Lilly, positioning itself uniquely in the market with a diverse portfolio and strategic focus on CNS disorders [1] Market Performance - Over the past month, ALKS has gained approximately 6.97%, reflecting strong investor confidence and positive market sentiment. This gain is significant in a volatile market, indicating optimism about the company's future prospects. However, in the past 10 days, ALKS experienced a slight decline of 2.10%, which may present a buying opportunity for investors [2][5] Growth Potential - ALKS shows a promising growth potential of 51.46%, suggesting that the stock is currently undervalued. This potential for appreciation makes it an attractive option for growth-oriented investors. The company's strong fundamentals are indicated by its Piotroski Score of 9, signifying robust financial health and efficient management practices [3][5] Target Price and Technical Indicators - The target price for ALKS is set at $43, aligning with its growth potential and current market dynamics. Achieving this target would represent a significant upside from its current trading levels, enhancing its appeal for investors. Additionally, ALKS has recently touched a local minimum, indicating that the stock may have bottomed out, which, combined with its strong fundamentals, enhances its attractiveness as a potential investment [4]

PresentationGreetings. Welcome to the Alkermes Conference Call. My name is Rob, and I'll be your operator for today's call [Operator Instructions] Please note, this conference is being recorded. I'll now turn the conference call over to Sandra Coombs, Senior Vice President of Investor Relations and Corporate Affairs. Sandy, you may now begin.Sandra CoombsSenior Vice President of Corporate Affairs & Investor Relations Welcome to the Alkermes plc conference call to discuss the results of the Vibrance-1 Phase ...

Sweden-listed cryptocurrency asset manager CoinShares is preparing to go public in the U.S.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.The company announced Monday (Sept. 8) that it had entered into a special p ...

Core Insights - Alkermes plc announced positive results from the Vibrance-1 phase 2 study of alixorexton, a novel orexin 2 receptor agonist for narcolepsy type 1, demonstrating significant improvements in wakefulness, cognition, and fatigue with once-daily dosing [1][2][4] Study Results - The Vibrance-1 study involved 92 patients and showed statistically significant improvements in mean sleep latency on the Maintenance of Wakefulness Test (MWT) at week six, with mean sleep latencies of approximately 24, 26, and 28 minutes for the 4 mg, 6 mg, and 8 mg doses respectively, compared to a baseline of about 3 minutes [4][5] - Alixorexton also achieved significant improvements in the Epworth Sleepiness Scale (ESS) scores, with baseline scores of 18.5 and reductions to the normal range (a score of 10) across all doses [4][5] - More than 40% of patients on the 6 mg and 8 mg doses experienced a 100% reduction in cataplexy during week six [4][5] Safety Profile - Alixorexton was generally well tolerated across all tested doses, with no serious treatment-emergent adverse events reported [6][4] - The most common mild to moderate adverse events included pollakiuria, insomnia, and blurred vision, with most events resolving within the first week of treatment [6][4] Future Plans - Alkermes plans to initiate a global phase 3 program for alixorexton in the first quarter of 2026, following the positive phase 2 results [8][4] - The company is also advancing other orexin-targeted therapeutics into first-in-human studies this year [8]

A month has gone by since the last earnings report for Alkermes (ALKS) . Shares have added about 4.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Alkermes due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid ...

– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition  –– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) a ...

Analyst's Disclosure:I/we have a beneficial long position in the shares of ALKS either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other s ...

Key Takeaways Alkermes plc (ALKS) reported earnings from continuing operations of 52 cents per share for the second quarter of 2025, which beat the Zacks Consensus Estimate of 41 cents. The company registered earnings of 53 cents per share in the year-ago quarter. Alkermes' total revenues of $390.7 million in the second quarter decreased 2.1% from the year-ago quarter due to lower manufacturing and royalty revenues. The top line, however, comprehensively beat the Zacks Consensus Estimate of $339 million. Ye ...